Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Which Therapy for Helicobacter pylori Infection?

Literature DB >> 22613622

Which Therapy for Helicobacter pylori Infection?

David Y Graham, Akiko Shiotani.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2012 PMID： 22613622 PMCID： PMC3383941 DOI： 10.1053/j.gastro.2012.05.012

Source DB: PubMed Journal: Gastroenterology ISSN： 0016-5085 Impact factor: 22.682

× No keyword cloud information.

15 in total

Review 1. Helicobacter pylori treatment in the era of increasing antibiotic resistance.

Authors: David Y Graham; Lori Fischbach
Journal: Gut Date: 2010-06-04 Impact factor: 23.059

2. Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?

Authors: Paul Moayyedi; Peter Malfertheiner
Journal: Am J Gastroenterol Date: 2009-12 Impact factor: 10.864

3. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors: Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal: Wien Klin Wochenschr Date: 2010-07-16 Impact factor: 1.704

4. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori.

Authors: M S Osato; R Reddy; S G Reddy; R L Penland; D Y Graham
Journal: Int J Antimicrob Agents Date: 2001-01 Impact factor: 5.283

5. Helicobacter pylori eradication therapy research: Ethical issues and description of results.

Authors: David Y Graham
Journal: Clin Gastroenterol Hepatol Date: 2010-07-23 Impact factor: 11.382

6. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.

Authors: Alessandro Federico; Gerardo Nardone; Antonietta G Gravina; Maria Rosaria Iovene; Agnese Miranda; Debora Compare; Paola A Pilloni; Alba Rocco; Luigi Ricciardiello; Riccardo Marmo; Carmelina Loguercio; Marco Romano
Journal: Gastroenterology Date: 2012-04-03 Impact factor: 22.682

Review 7. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.

Authors: Luigi Gatta; Nimish Vakil; Gioacchino Leandro; Francesco Di Mario; Dino Vaira
Journal: Am J Gastroenterol Date: 2009-10-20 Impact factor: 10.864

8. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.

Authors: Richard J Saad; Philip Schoenfeld; Hyungjin Myra Kim; William D Chey
Journal: Am J Gastroenterol Date: 2006-03 Impact factor: 10.864

9. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies.

Authors: T Lind; F Mégraud; P Unge; E Bayerdörffer; C O'morain; R Spiller; S Veldhuyzen Van Zanten; K D Bardhan; M Hellblom; M Wrangstadh; L Zeijlon; C Cederberg
Journal: Gastroenterology Date: 1999-02 Impact factor: 22.682

Review 10. Efficient identification and evaluation of effective Helicobacter pylori therapies.

Authors: David Y Graham
Journal: Clin Gastroenterol Hepatol Date: 2008-10-30 Impact factor: 11.382

15 in total

1. Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.

Authors: Boudewijn L M de Jonge; Amy Kutschke; Joseph V Newman; Michael T Rooney; Wei Yang; Christer Cederberg
Journal: Antimicrob Agents Chemother Date: 2015-02-02 Impact factor: 5.191

Which Therapy for Helicobacter pylori Infection?

Review 1. Helicobacter pylori treatment in the era of increasing antibiotic resistance.

2. Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?

3. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

4. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori.

5. Helicobacter pylori eradication therapy research: Ethical issues and description of results.

6. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.

Review 7. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.

8. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.

9. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies.

Review 10. Efficient identification and evaluation of effective Helicobacter pylori therapies.

1. Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.

2. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.

Review 3. Eradication of Helicobacter pylori Infection.

4. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy.

Review 5. Helicobacter pylori: future perspectives in therapy reflecting three decades of experience.

Review 6. Eradication of Helicobacter pylori infection: which regimen first?

7. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.

Review 8. Antibiotic treatment for Helicobacter pylori: Is the end coming?

Review 9. Kyoto global consensus report on Helicobacter pylori gastritis.

Review 10. Therapy of Helicobacter pylori: present medley and future prospective.